Article

BRAF p.V600E Mutation as Acquired Resistance Mechanism of Lorlatinib in a ROS1 Rearrangement Lung Adenocarcinoma Patient with Primary Ceritinib Resistance

2021-09-14

Abstract excerpt

Both crizotinib and ceritinib are recommended as first-line theray for NSCLC with ROS1 rearrangements, with the latter having stronger infiltration ability across blood-brain barrier. Here we report for the first time that a brain metastatic adenocarcinoma patient with CD74-ROS1 rearrangement was sensitive to crizotinib but resistant to ceritinib. Intracranial progression happened after 7 months of crizotinib, and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e4aa8720-acf1-5366-8b59-bc4ba71bb124
DOI: 10.21203/rs.3.rs-882880/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

BRAF p.V600E Mutation as Acquired Resistance Mechanism of Lorlatinib in a ROS1 Rearrangement Lung Adenocarcinoma Patient with Primary Ceritinib ResistanceDOI 10.21203/rs.3.rs-882880/v1Read

Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.Semantic proximity Read

Acquired resistance to crizotinib from a mutation in CD74-ROS1.Semantic proximity Read

Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion.Semantic proximity Read

Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma.Semantic proximity Read

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.Semantic proximity Read

Importance of ROS1 fene fusions in non-small cell lung cancerSemantic proximity Read

Temporal Heterogeneity of ROS1 Fusion and Braf Fusion Conferred Resistance to First-and Third-generation EGFR Tkis: a Case Report.Semantic proximity Read

EZR-ROS1 rearrangement as a novel mechanism of acquired resistance to EGFR-TKIs in NSCLC: a case report and literature review.Semantic proximity Read

Identification of A Novel FRK-ROS1 Fusion Variant in Advanced Non-Small Cell Lung Cancer with Brain Metastases and Remarkable Response to CrizotinibSemantic proximity Read

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant AlterationsSemantic proximity Read

Prolonged Response to Afatinib and Crizotinib in a Rare Case of EGFR-, HER2-, MET- and ROS1-Alterated Lung Adenocarcinoma.Semantic proximity Read

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical modelsSemantic proximity Read